Wells Fargo & Company Sutro Biopharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding STRO
# of Institutions
124Shares Held
63MCall Options Held
200Put Options Held
27.6K-
Suvretta Capital Management, LLC New York, NY7.71MShares$34.7 Million0.94% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$31.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.45MShares$20 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.36MShares$19.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$16 Million0.0% of portfolio
About SUTRO BIOPHARMA, INC.
- Ticker STRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,161,500
- Market Cap $235M
- Description
- Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...